Physician profile
Mallory Willis
NPI 1306308309
$1,529.36
in general payments reported to CMS, 2019-2025
17 companies · $788 in 2025
The $788 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $36.97 · 2023: $380 · 2024: $324 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.12 | 2023-2025 | Vraylar, Ubrelvy |
| Abbott Laboratories | $401.62 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $141.19 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $93.91 | 2023-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $78.17 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $61.48 | 2024-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.52 | 2023-2024 | Jardiance |
| Edwards Lifesciences Corporation | $43.75 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $41.57 | 2024-2025 | Airsupra |
| Mylan Specialty L.P. | $39.34 | 2023-2024 | Yupelri |
| Coloplast Corp | $36.97 | 2022 | |
| Axsome Therapeutics, INC. | $36.09 | 2024-2025 | Auvelity |
| Pfizer INC. | $34.38 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $17.87 | 2024 | |
| Exact Sciences Corporation | $15.04 | 2025 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $14.15 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.